Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
May 2nd, 2011
This protocol describes a general procedure for studying recombinant receptor-binding domain (RBD)-based subunit vaccines against SARS. It includes methods for transfection and expression of RBD protein in 293T cells, immunization of mice with RBD and detection of neutralization activity of mouse sera using an established SARS pseudovirus neutralization assay.
Overview
This protocol outlines a method for evaluating recombinant receptor-binding domain (RBD)-based subunit vaccines against SARS. It details the transfection of 293T cells to express RBD protein, immunization of mice, and assessment of neutralization activity using a SARS pseudovirus neutralization assay.
Key Study Components
Area of Science
- Vaccine development
- Immunology
- Virology
Background
- Recombinant vaccines can induce immune responses against viral infections.
- SARS-CoV poses significant health risks, necessitating effective vaccine strategies.
- Pseudovirus assays provide a safer alternative to live virus assays.
- Neutralizing antibodies are crucial for protection against viral infections.
Purpose of Study
- To develop a recombinant vaccine targeting the SARS RBD protein.
- To evaluate the immunogenicity of the RBD protein in mice.
- To assess the neutralization potential of sera from immunized mice.
Methods Used
- Transfection of 293T cells with RBD plasmid to express the protein.
- Purification of RBD protein from cell culture supernatant.
- Immunization of mice with RBD protein and adjuvant.
- Neutralization assays using SARS pseudovirus to measure antibody response.
Main Results
- Successful expression and purification of RBD protein from 293T cells.
- Immunization induced neutralizing antibodies in mice.
- Neutralization assays demonstrated the efficacy of the immune response.
- The pseudovirus assay proved to be a safe and effective method for evaluation.
Conclusions
- The RBD-based vaccine shows promise for inducing protective immunity against SARS.
- Pseudovirus neutralization assays are a viable alternative to live virus assays.
- Further studies are needed to optimize vaccine formulations and dosing.
Frequently Asked Questions
Executive Industry Relevance
This protocol enables biopharma teams to evaluate recombinant subunit vaccine candidates using a safe pseudovirus neutralization assay, supporting early immunogenicity assessment without live pathogen handling. The approach provides quantitative neutralization titers that inform go/no-go decisions in vaccine discovery pipelines. It offers a scalable, reproducible method for assessing antigenicity of RBD-based constructs against SARS-CoV and other class I fusion protein viruses.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of RBD antigenicity by measuring neutralizing antibody induction in vivo.
- Operational Value: Uses mammalian 293T expression to produce properly folded, glycosylated RBD protein with high immunogenicity.
Screening & Assay Development
- Scientific Value: Establishes a pseudovirus neutralization assay that quantifies serum neutralizing activity via luciferase readout.
- Operational Value: Eliminates need for BSL-3 containment, allowing safe, high-throughput screening of vaccine candidates.
Translational & Preclinical Research
- Scientific Value: Supports dose-response analysis through serial serum dilution and NT50 titer calculation.
- Operational Value: Uses adjuvant-formulated protein immunization in mice to model human immune response kinetics.
Pipeline & Workflow Integration
The method fits within early discovery to preclinical transition, providing immunogenicity data after antigen expression and before lead optimization.
- Discovery Biology: Tests hypothesis that RBD elicits neutralizing antibodies via calcium phosphate transfection and protein purification.
- Screening: Delivers reproducible quantitative outputs (NT50 titers) for comparing vaccine formulations.
- Analytics: Uses luciferase-based signal detection to measure infection inhibition, enabling statistical comparison of immune sera.
- Translational Research: Models human-relevant immune response through murine vaccination and serum collection at defined intervals.
- Enterprise Reuse: Pseudovirus platform adaptable to other class I fusion protein viruses (HIV, RSV, Ebola, influenza, Nipah, Hendra).
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking antigen expression to functional neutralization outcome.
- Operational Value: Standardized transfection, purification, and assay steps improve reproducibility across teams.
- Strategic Value: Enables early de-risking of vaccine candidates by predicting protective immunity potential.
- Portfolio Impact: NT50 titers support risk-adjusted prioritization of RBD constructs for advancement.
Implementation Considerations
- Requires expertise in mammalian cell transfection, protein purification, and adjuvant emulsion preparation.
- Dependent on calcium phosphate transfection equipment, nickel NTA columns, concentrators, and luminometers.
- Necessitates cross-team standardization of serum heat inactivation, complement removal, and assay timing.
- Adaptation to other viruses requires pseudovirus generation with relevant envelope and receptor pairs.
- Limited by murine model translation; human immunogenicity confirmation requires further clinical study.
Biopharma FAQs
Chapters in this video
0:05
Title
1:01
Introduction
1:52
Recombinant SARS-CoV RBD Protein Preparation
4:40
Mouse Immunization and Sample Collection
5:56
Preparation of SARS Pseudovirus in 293T Cells
6:53
SARS Pseudovirus Titration and Neutralization Assay
11:10
Evaluation of Recombinant RBD-induced Neutralizing Activity
11:36
Conclusion
